Genetic testing has quickly grown from being very rare, to prominently weaving into prenatal care, cancer care, and nearly all specialties of medicine including neurology, cardiology, and ophthalmology.
To understand how health plans are integrating this rapidly changing test landscape into their genomic benefits management (GBM) approach, InformedDNA partnered with medical technology service provider, Veranex, on an in-depth voice of the customer (VOC) study with medical directors and other senior leaders at health plans in the U.S.
In Q2 of 2022, medical executives at organizations ranging in size from 500,000 to 20 million lives candidly answered questions about their current GBM situation and future needs.
In this VOC research report, we showcase the research results and discuss how solid policy foundations coupled with guidance on how to apply them are the absolute cornerstones for increasing decision-maker confidence and staying on top of the changing genetic testing landscape.
Download your copy of this informative research report now.